Dietary factors and microRNA-binding site polymorphisms in the *IL13* gene: risk and prognosis analysis of colorectal cancer

Supplementary Materials

Supplementary Table 1: The predicted biological impact of candidate SNPs located in microRNAbinding site of *IL13*. See Supplementary_Table_1

Supplementary Table 2: Univariate and multivariate logistic regression analyses for the association between environmental factors and colorectal cancer risk. See Supplementary_Table_2

Supplementary Table 3: Demographic and clinical pathological characteristics of colorectal cancer patients. See Supplementary_Table_3

Prognosis factor	Univariate analysis		Multivariate analysis	
	Mean survival times (months) (95% CI)	Hazard ratio (HR) (95% CI)	Hazard ratio (HR) (95% CI)	<i>P</i> value
Location of primary tumor				
Colon	77.17 (68.84–85.51)	1		
Rectum	70.18 (64.81–75.55)	1.37 (0.94–2.00)		
General classification of tumor				
Protrude type	81.08 (73.58-86.57)	1	1	
Invasive and ulcerative type	61.70 (54.10-69.30)	2.02 (1.44-2.84)	1.73 (1.23–2.44)	0.002
Other types	11.50 (8.04–14.97)	9.83 (1.32-73.23)	14.92 (1.95–14.47)	0.009
Histological classification of tur	nor			
Adenocarcinoma	71.33 (66.22–76.43)	1		
Mucinous adenocarcinoma	75.75 (65.52–85.98)	0.86 (0.56–1.33)		
Other types	80.17 (51.38–108.95)	0.55 (0.14-2.23)		
Stage of Dukes'				
I	92.44 (83.81-101.07)	1	1	
II	85.27 (79.30–91.23)	1.67 (0.78-3.54)	1.60 (0.71-3.61)	0.26
III	59.70 (51.71-66.43)	4.28 (2.06-8.90)	4.29 (1.95-9.42)	< 0.001
IV	22.35 (15.05-29.65)	15.72 (6.78–36.48)	14.79 (5.97–36.66)	< 0.001
Metastasis				
No	54.52 (47.72–61.32)	1		
Yes	86.29 (81.12–91.47)	3.11 (2.21-4.37)		
Chemotherapy treatment				
No	73.85 (67.28-80.41)	1		
Yes	72.11 (65.86–78.36)	0.96 (0.69–1.34)		
rs847				
GG	67.82 (61.39–74.26)	1		
AG	76.86 (70.13-83.60)	0.72 (0.51-1.01)		
AA	83.18 (65.97–100.38)	0.51 (0.22–1.17)		
rs848				
GG	67.91 (61.48–74.35)	1		
GT	76.08 (69.32-82.84)	0.75 (0.53-1.06)		
TT	78.80 (60.49–97.11)	0.60 (0.28–1.30)		
rs1295685				
CC	66.94 (60.46–73.43)	1		
СТ	77.37 ((70.59–84.14)	0.69 (0.49-0.97)		
TT	84.57 (68.08–101.06)	0.47 (0.20-1.07)		

Supplementary Table 4: Cox-regression on the association between clinical pathological characteristics, microRNA-binding site polymorphisms in *IL13* and the prognosis of CRC